This protocol is judged by an institutional review board, an unbiased team that critiques any medical trials involving individuals. If a review will involve a Plan I drug, once the board approves the protocol as ethical, the researchers should apply for an investigational new drug (IND) variety from the FDA.The good thing is, other companies with